Hairy cell leukemia

被引:0
作者
Troussard, Xavier [1 ,2 ,3 ]
Cornet, Edouard [1 ]
机构
[1] CHU Cote Nacre, Hematol Lab, Caen, France
[2] CHU Cote Nacre, Hemopathies Malignes Basse Normandie, Caen, France
[3] Univ Caen Basse Normandie, UPRES EA 3919, UFR Med Caen, Caen, France
来源
HEMATOLOGIE | 2010年 / 16卷 / 06期
关键词
hairy cell leukemia; purine nucleoside analogues; cladribine; pentostatin;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hairy-cell leukemia (HCL) is a rare hematologic malignancy. HCL diagnosis can be difficult and the variant form of HCL (HCL-V) has similarities with B-cell prolymphocytic leukemia or splenic marginal zone lymphoma. We describe the different features of HCL, particularly typical HCL (HCL-C) and HCL-V. HCL prognosis was transformed by the introduction of purine nucleoside analogues such as Cladribine or Pentostatin. Both agents are highly effective and the survival of HCL patients is simlilar to that of the general population. The study of residual disease is important and the negativity could mean cure of the disease. The patients refractory to purine nucleoside analogues could benefit treatments with monoclonal antibodies.
引用
收藏
页码:432 / 442
页数:11
相关论文
共 107 条
[61]  
Orchard JA, 1998, BRIT J HAEMATOL, V100, P677
[62]   Second malignancy in hairy cell leukaemia: No evidence of increased incidence after treatment with interferon alpha [J].
Pawson, R ;
AHern, R ;
Catovsky, D .
LEUKEMIA & LYMPHOMA, 1996, 22 (1-2) :103-106
[63]  
Piris M, 2008, IARC LYON, P191
[64]   LASTING REMISSIONS IN HAIRY-CELL LEUKEMIA INDUCED BY A SINGLE INFUSION OF 2-CHLORODEOXYADENOSINE [J].
PIRO, LD ;
CARRERA, CJ ;
CARSON, DA ;
BEUTLER, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (16) :1117-1121
[65]   ALPHA-INTERFERON FOR INDUCTION OF REMISSION IN HAIRY-CELL LEUKEMIA [J].
QUESADA, JR ;
REUBEN, J ;
MANNING, JT ;
HERSH, EM ;
GUTTERMAN, JU .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (01) :15-18
[66]   Long-lasting decrease of CD4+/CD45RA+ T cells in HCL patients after 2-chlorodeoxyadenosine (2-CdA) treatment [J].
Raspadori, D ;
Rondelli, D ;
Birtolo, S ;
Lenoci, M ;
Nardi, G ;
Scalia, G ;
Sestigiani, C ;
Tozzi, M ;
Marotta, G ;
Lauria, F .
LEUKEMIA, 1999, 13 (08) :1254-1257
[67]   Eradication of minimal residual disease in hairy cell leukemia [J].
Ravandi, F ;
Jorgensen, JL ;
O'Brien, SM ;
Verstovsek, S ;
Koller, CA ;
Faderl, S ;
Giles, FJ ;
Ferrajoli, A ;
Wierda, WG ;
Odinga, S ;
Huang, XL ;
Thomas, DA ;
Freireich, EJ ;
Jones, D ;
Keating, MJ ;
Kantarjian, HM .
BLOOD, 2006, 107 (12) :4658-4662
[68]  
Ribeiro P, 1999, CANCER-AM CANCER SOC, V85, P65, DOI 10.1002/(SICI)1097-0142(19990101)85:1<65::AID-CNCR9>3.0.CO
[69]  
2-B
[70]   Current treatment options in hairy cell leukemia and hairy cell leukemia variant [J].
Robak, Tadeusz .
CANCER TREATMENT REVIEWS, 2006, 32 (05) :365-376